Iambic Therapeutics, Inc. (IAM)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Thomas Miller Ph.D.
|
Co-Founder, CEO, Secretary & Director | 906.2k | -- | 1979 |
|
Dr. Michael Secora Ph.D.
|
Chief Corporate Development Officer & CFO | 932.66k | -- | 1983 |
|
Dr. Neil Josephson M.D.
|
Chief Medical Officer | -- | -- | 1961 |
|
Mr. Laurent Gomez Ph.D.
|
Senior VP & Head of Discovery | -- | -- | -- |
|
Mr. Matt Welborn Ph.D.
|
Senior Vice President of Machine Learning | -- | -- | -- |
Iambic Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 171
Description
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
